Det håper jeg du har rett i.
Det kan bli dyrt🙂.
Denne har alle forutsetninger for å bli vinterens store børsvinner.
Det tekniske er med oss.
Det fundamentale er med oss.
Den er allerde godt shortet, så mye skal kjøpes.
5 Likes
Jawohl! Gleiche Erfahrung hier. War schon voll beladen, schaffte aber auch noch ein paar extra tausen!
2 Likes
Kan det være riktig at Folketrygdefondet har nå ca 1,3 mill aksjer til utlån ??
Folkesvikerfondet 
3 Likes
Helt forståelig og økonomisk klokt at langsiktige eiere som vårt alles Folketrygdefond benytter anledningen til å låne ut sine aksjer for å tjene litt penger på sine aksjer inntil man langt der fremme er kommet i mål på en eller annen måte.
Den eneste innvendingen kan være om dette presser kursen ned slik at utvanningen blir stor ved en eventuell emisjon. Men en emisjon er neppe særlig aktuell for nåværende i Nanov sitt tilfelle.
Had to google translate there! 
. German … Gosh! . Trying to hit a low blow on a good NANO day? . Hope it made you feel better. 
1 Like
Det stemmer at de har ca. 1.3 millioner aksjer mindre fra ath antall aksjer eid. Og ut ifra tidligere bevegelser hos de så kan man vel helle mot å tro at de ikke har solgt, men at det er utlån👍
2 Likes
Og trolig ligger det nok en god del skjult under grensa også, så de er nok langt ifra alene om å låne ut 
Får håpe de siste dagers opptur er en liten reprising som fortsetter inn mot Q3 og R&D, kan bli en fin høst/vinter da når fullrekruttert paradigme kommer 
18 Likes
Du var vel ikke på toget i 2016?
EANM21
OP-0283
Global Tumour Absorbed Dose Heterogeneity for
Patients Treated with 177-Lilotomab Satetraxetan
J. Blakkisrud1,2, A. Løndalen1,3, J. Dahle4
, A. Kolstad5
, C. Stokke1,2; 1
Division of Radiology and Nuclear Medicine, Oslo University
Hospital, Oslo, NORWAY, 2
Department of Physics, University of
Oslo, Oslo, NORWAY, 3
Faculty of Medicine, University of Oslo, Oslo,
NORWAY, 4
Nordic Nanovector ASA, Oslo, NORWAY, 5
Department
of Oncology, Oslo University Hospital, Oslo, NORWAY.
Aim/Introduction: 177-Lu-lilotomab satetraxetan is a
radioimmunoconjugate currently undergoing clinical trials to
treat patients with indolent non-Hodgkin B-cell lymphoma.
Cumulative dose voxel histograms (cDVH) can be used to
assess the distribution of absorbed dose. In the current
work we aimed to investigate the relationship between
cDVH parameters for tumour tissue and clinical response.
Materials and Methods: Fourteen patients with indolent
non-Hodgkin lymphoma from the phase 1/2a LYMRIT37-01
trial injected with 177-Lu-lilotomab satetraxetan (median
1362, range 756-2189 MBq) and subjected to post-therapy
SPECT/CT imaging were included. Manual masking of
physiological uptake and a global threshold previously
found for this patient group was used to segment tumour
regions. Absorbed dose rate maps were derived from SPECT/
CT-images acquired 96 hours post injection. A patientaveraged efective half-life calculated from the total activity
in the tumours 96 and 168 hours post injection was used to
form dose maps. The D98 and D02, the minimum absorbed
dose covering 98 and 2 percent of the patient total tumour
tissue respectively was calculated. A heterogeneity index
(HI) defned as (D02-D98)/D50 was also found. An analysis
performed on individual tumour volumes, defned as
connected regions in the tumour mask, where the relative
diference between minimum and maximum D50-absorbed
dose, to measure intra-patient variation. Patients were
grouped into complete and partial responders (CR+PR), and
stable disease and progressive disease (SD+PD). Spearman
rank was used to test correlation between D98, D02 and
D50-values and the Mann-Whitney-U-test was used to test
diferences between groups. Results: Patient global D98-
absorbed doses ranged from 0.26 to 2.60 Gy. The patient
global D02-values ranged from 0.85 to 8.41 Gy. There was
a higher patient global D98-absorbed dose for the CR+PRgroup (median 0.87, range 0.26-2.62 Gy) compared to the
SD+PD-group (median 0.55, range 0.32-1.37 Gy) but this
diference was not signifcant (p = 0.25). There were strong
correlations between the DVH-parameters (rho 0.95-0.97,
p<10-7 ). The HI did not difer between the two groups,
median HI (ranges) were 1.50 (1.10-1.60) and 1.40 (1.04-1.76)
for the CR+PR and SD+PD-group respectively. The number
of tumour regions in the patients varied from a single region
to 23 regions. Intra-patient relative diference in D50-values
ranged from 30 to 140 %. Conclusion: Estimated cDVHparameters calculated from global threshold segmented
tumour regions from post therapy SPECT/CT-images proved
insufcient to explain diferences between clinical response
for patients treated with 177-Lu-lilotomab satetraxetan.
Possible future directions encompass incorporation
of baseline FDG-PET/CT-information to defne tumour
anatomy. References: None
Fullt program:
8 Likes
Fra januar 2015.
Der smalt vi over 27. Høyeste kurs siden 25.mai. Shortskvis i dag og?
3 Likes
Det er tidevannet… på vei mot enrollment complete 
7 Likes
Her er en video med dans dedikert til shorter pakket:) god morgen:)
1 Like
Denne oppgangen fra et veldig stabilt nivå er nesten litt mistenkelig. Lekket noe informasjon som ikke er børsmeldt?
Jævelig fart i algoritmen i dag. Stolpene flyr opp og ned som gale.
Digg da
5 Likes
Med combigene rush i årene så skriver jeg dette> Nano kan overraske noe så grønn jævlig med enrollment complete om det var noe sannhet i deres tidligere guiding ang 7 i mnd når corona avtar.
Kombinert med en saftig ketchup effekt så kan de snuse på 120 tallet most soon
4 Likes
Nano og Ulti er to kvalitets biotech aksjer… heia for begge
3 Likes